Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Sep 15:416:117011.
doi: 10.1016/j.jns.2020.117011. Epub 2020 Jul 4.

Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide

Luca Bollo  1 , Tommaso Guerra  1 , Davide Fiore Bavaro  2 , Laura Monno  2 , Annalisa Saracino  2 , Gioacchino Angarano  2 , Damiano Paolicelli  1 , Maria Trojano  1 , Pietro Iaffaldano  3
Affiliations
Case Reports

Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide

Luca Bollo et al. J Neurol Sci. .
No abstract available

Keywords: Antibodies; COVID-19; Fingolimod; Multiple sclerosis; Seroconversion; Teriflunomide.

PubMed Disclaimer

Conflict of interest statement

Pietro Iaffaldano has served on scientific advisory boards for Biogen Idec and has received funding for travel and/or speaker honoraria from Sanofi-Aventis, Biogen Idec, Teva and Novartis. Maria Trojano has received honoraria for consultancy or speaking from Biogen, Sanofi-Aventis, Merck Serono and Bayer-Schering and research grants from Merck Serono, Biogen and Novartis. Damiano Paolicelli received honoraria for consultancy and/or speaking from Biogen Idec, Merck-Serono, SanofiAventis, TEVA, Novartis and Genzyme. No conflicts of interests need to be declared for Luca Bollo, Tommaso Guerra, Davide Fiore Bavaro, Laura Monno, Annalisa Saracino and Gioacchino Angarano.

Figures

Fig. 1
Fig. 1
(a) CD3+ and CD3 + CD4+ lymphocyte count after start of therapy with fingolimod until the hospitalization for Covid-19 in case 1 (b) anti spike protein S1 receptor binding domain (S1RBD) and anti-nucleocapsid (NP) IgG response to SARS-CoV-2 in patient 1 and 2 detected at 7,21,28,35 days after diagnosis. Dotted line: Cut off of anti-NP IgG positivity (=0.199). Continuous line: Cut off of anti-S1RBD IgG positivity (=1.000). Od450: optical density measurements using a microplate reader with a 450 nm filter.
See this image and copyright information in PMC

References

    1. COVID-19 Situation Reports. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio... (Accessed May 17, 2020)
    1. Conforti C., Giuffrida R., Dianzani C., Di Meo N., Zalaudek I. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action. Dermatol. Ther. 2020:e13298. doi: 10.1111/dth.13298. Published online March 11. - DOI - PMC - PubMed
    1. Bavaro D.F., Fiordelisi D., Angarano G., Monno L., Saracino A. Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections. Expert Opin. Drug Saf. 2020:1–25. doi: 10.1080/14740338.2020.1767585. Published online May 31. - DOI - PubMed
    1. Blanc C.A., Grist J.J., Rosen H., Sears-Kraxberger I., Steward O., Lane T.E. Sphingosine-1-phosphate receptor antagonism enhances proliferation and migration of engrafted neural progenitor cells in a model of viral-induced demyelination. Am. J. Pathol. 2015;185(10):2819–2832. doi: 10.1016/j.ajpath.2015.06.009. - DOI - PMC - PubMed
    1. Scott L.J. Teriflunomide: a review in relapsing-remitting multiple sclerosis. Drugs. 2019;79(8):875–886. doi: 10.1007/s40265-019-01135-8. - DOI - PubMed